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This report describes Diversion Alert, a unique online tool aimed
at reducing misuse and diversion of prescription drugs, and re-
ports the results of a 1-year evaluation of Diversion Alert’s im-
pact in Maine. We used a quasi-experimental research design to
compare survey data in Maine with those of neighboring states
(New Hampshire and Vermont, 2013 and 2014). Compared with
their counterparts in New Hampshire and Vermont who did not
use Diversion Alert, prescribers and pharmacists in Maine who
used Diversion Alert increased their communication with patients
and other providers involved in their patients’ care, became aware
of patients arrested for prescription drugs possession or diversion,
used best practices associated with prevention or detection of ad-
diction and diversion more frequently,  and attributed positive
changes in their prescribing practices to Diversion Alert. In com-
bination with other state and federal programs, Diversion Alert
may be an effective tool to help prevent the misuse of opioid med-
ications.
Introduction
The epidemic of opioid overdose is well-documented (1), and it is
known that prescription drug misuse and diversion are a part of the
problem (2,3). The United States’ ongoing prescription drug ab-
use epidemic is leading to a dramatic increase in opioid overdoses
and overdose deaths nationwide. Every day, 46 people die as a res-
ult of overdose from prescription painkillers (4). Including heroin
overdoses makes deaths from opioid overdoses the leading cause
of unintentional death for Americans, rising 14% from 2013 to
2014 (5). Although they are not the only source, physicians are the
leading source of prescription painkillers for people at high risk
for painkiller overdose (2). This statistic points to a fundamental
concern associated with prescription abuse — a medical system
that may unintentionally cause addiction rather than preventing
and treating it. Medical professionals are ideally positioned to in-
tervene with patients who struggle with addiction and could more
effectively do so if given tools and resources that help them identi-
fy and respond to vulnerable patients (ie, those who are at risk for
overdose or who are illegally diverting prescription medicines).
An array of interventions have been implemented nationally or at
state levels to limit prescription opioid misuse (6). For example,
naloxone availability and treatment programs have multiplied (7),
changes have occurred in clinical guidelines and in the develop-
ment of abuse resistant opioids (8), and adoption of prescription
drug monitoring programs (PDMPs) has been almost universal (in
49 of 50 states), although characteristics of these programs vary by
state (9). Although federal efforts, including grant funding, are
substantial and span several federal agencies (eg, Substance Ab-
use and Mental Health Services Administration, Health Resources
and Services Administration, Drug Enforcement Agency), there
has not yet been a systematic approach to linking health system
and law enforcement efforts as a means to more effectively ad-
dress prescription drug abuse and diversion. Prescription drug di-
version has been defined as the unlawful channeling of regulated
pharmaceuticals from legal sources to the illicit marketplace (10).
Diversion occurs at various points within the medical distribution
system — via wholesale distributors, medical offices, retail phar-
macies, or patients themselves (11).
It is well-recognized that the issue of drug abuse, misuse, and di-
version must be approached from several angles. In this report, we
outline the components of a potentially useful tool for linking
medical and enforcement systems by providing drug arrest  re-
cords to medical professionals. We also describe the preliminary
results obtained to date on this innovative strategy.
Diversion Alert
Diversion Alert (DA) is a program unique to Maine and was estab-
lished in 2009 with federal funds from the Office of National Drug
Control Policy’s Drug Free Communities Support Program, which
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were awarded to a community coalition in northern Maine. When
federal funds expired in 2012, the program received state funding
from the Maine Attorney General’s Office. Diversion Alert aims
to 1) provide medical professionals with a source of information to
identify patients who are at risk for overdose, in need of addiction
treatment, or engaged in illegal pharmaceutical distribution; 2) in-
crease attentiveness to prescribing practices; and 3) increase use of
prescribing practices that help reduce abuse and diversion of pre-
scription drugs. The core components of Diversion Alert are 1)
monthly drug arrest reports from the previous month, consisting of
public drug arrest data that are organized by geographic region (ie,
by county and by state); 2) online, mobile-friendly, searchable
drug arrest database containing an 11-month historical record of
public drug arrest data submitted to Diversion Alert and access-
ible to registrants any time; and 3) research-based educational re-
sources to assist in responding to patients charged with prescrip-
tion drug or illegal drug crimes.
DA provides access to prescription (schedule II-IV) and illegal
drug charge data for medical professionals (actively licensed phar-
macists, prescribers, and medical office staff authorized to parti-
cipate on behalf of prescribers or pharmacists), so they can re-
spond to patients in need of intervention. Significantly, Diversion
Alert  distributes  drug charge data  rather  than conviction data.
There are 2 types of drug charges: an arrest and a summons. An
arrest gives notice to a person that he or she is being charged with
a crime. The person who is arrested is detained and kept in cus-
tody until he or she can post bail or the criminal charges are re-
solved. A summons gives notice to an individual that he or she is
being charged with a crime, but the individual is not detained. In
contrast, a conviction is a formal declaration by a court that a per-
son has been found to have committed (is guilty of) a crime. The
State must prove a person’s guilt beyond a reasonable doubt to ob-
tain a conviction. The fact that a person has been arrested or re-
ceived a summons does not guarantee that the person will be con-
victed of a crime.
Provision to prescribers of drug charge data, rather than convic-
tion data, may be a point of concern; however, there are 3 keys
points to consider. First, in Maine it takes from 12 to 18 months
for a person charged with a drug crime to be convicted. Because
individuals are generally released shortly after an arrest, there is a
long period  from charge  to  conviction  during  which  a  person
could be putting himself  or others at  risk as a result  of an un-
treated  addiction  or  undetected  diversion  of  pharmaceuticals.
Therefore, it may be safer to use drug charge data as soon as they
are available (within a few weeks of the date of charge) rather than
to use conviction data. Second, anecdotal evidence from discus-
sion with law enforcement in Maine suggests that more than 90%
of drug charges end in a conviction. Additionally, a study conduc-
ted by the Bureau of Justice Statistics found that 93% of drug de-
fendants adjudicated during 2006 were convicted (12). Most im-
portantly, Diversion Alert is intended to be used as a resource to
improve patient care and not as a punitive measure against pa-
tients. When a medical professional discovers a patient on a Diver-
sion  Alert  report,  that  discovery  is  an  indication  both  that
something may be occurring and that additional work should be
done (eg, talking to the patient and to other professionals who
share the patient’s treatment, checking the prescription drug mon-
itoring program) to get a more complete picture of what is going
on with the patient.
As a public health intervention, Diversion Alert is based on “the
public  health  model,  which  demonstrates  that  problems  arise
through relationships and interactions among an agent . . . a host . .
. and the environment” (13). That is, in some instances prescrip-
tion drug abuse and diversion arise from the interactions among
the patient, the prescriber, and the prescribing environment within
the medical system. In accordance with the Transtheoretical Mod-
el of behavior change (14), health care providers who begin using
Diversion Alert will transition from being unaware of the extent of
prescription drug abuse in Maine to a point at which they will be
ready to change prescribing behaviors in response to patients they
discover abusing or diverting prescriptions or to prevent future di-
version and abuse. The specific prescribing behaviors the pro-
gram seeks to increase are practices recommended in the literature
(eg, urine drug screens, random pill counts, frequent use of pre-
scription drug monitoring programs) for reducing abuse and diver-
sion of prescription drugs for any person prescribed schedule II
through IV controlled substances. By providing information to
prescribers that aims to change prescriber perceptions and behavi-
ors, patient addiction and diversion may be more effectively ad-
dressed and prevented, and fewer pharmaceuticals may be illeg-
ally diverted into communities.
Methods
The Diversion Alert evaluation used a quasi-experimental, pre/
post  design with New Hampshire and Vermont as comparison
groups. The Provider Awareness and Practice Survey, developed
for this study and used as the basis for this evaluation, has 40
questions and exists both in paper form and online. The survey
questions fall into the following categories: general (items 1–3 re-
garding professional role, state of practice, and zip code), beliefs
about diversion (items 4–6), current practice with emphasis on
communication and prescribing habits (items 7–19), use of univer-
sal precautions in practice (items 20–26), use of screenings and
other assessments (items 27–35), and behavioral response to pa-
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tients who have been arrested for illegal prescription drug activit-
ies (items 36–40). The survey was reviewed for face validity and
content validity by 3 expert evaluators and medical and law en-
forcement professionals who serve on DA’s Statewide Advisory
Board.
The Provider Awareness and Practice Survey, hosted on Survey
Gizmo, was distributed during 2 periods, 1 year apart (summer/fall
of 2013 and summer/fall of 2014) through bulk mailings to act-
ively licensed prescribers and pharmacists in all 3 states. Mailing
lists  were obtained through professional  associations,  through
databases maintained by states, or both. A cover letter with the In-
ternet address and the paper form of the survey with a business-
reply envelope were mailed to all prescribers and pharmacists in
the states under study.
Descriptive statistics were used to calculate frequencies of re-
sponses. Analysis of Variance was used to detect difference across
states, and t tests were used to detect differences within a state
over time. Alpha was set at .05.
Results
In 2013, 1,811 respondents participated in the pre-evaluation, and
782 respondents participated in the 2014 postevaluation (Table 1).
Posttest respondents and their professional grouping indicated that
most responders were prescribers, and 10% to 20% were phar-
macists. Less than 9% identified as “medical office staff” or “oth-
er.”
In 2013, 87% of Maine survey respondents reported yes to the
item, “There is a prescription abuse/diversion problem in my local
area.” One year later, 98% agreed. By 2014, nearly all respond-
ents in Vermont believed that there was a prescription abuse/diver-
sion problem in their local area (96%). In New Hampshire, 76%
agreed. The percentages increased by more than 10% between
2013 and 2014 for Maine and Vermont but not for New Hamp-
shire.
For the item, “In the past 6 months, I have become aware of pa-
tients in my care arrested for prescription drug possession or di-
version,” 49% of Maine respondents said yes in 2014, signific-
antly more than either New Hampshire (21%; P < .05) or Ver-
mont (29.6%; P < .05).
With regard to communicating with health care providers who
share a patient’s treatment plan, Maine respondents increased from
2013 to 2014 more than the other states (0.46 on a 4-point Likert
scale [1 = never, 2 = somewhat, 3 = a lot, and 4 = all the time]
compared with 0.04 for New Hampshire and 0.01 for Vermont).
Communicating with law enforcement decreased from 2013 to
2014 for Maine respondents (−0.25 on 4-point Likert scale com-
pared with −0.05 for Vermont and +0.04 for New Hampshire). By
2014, Maine respondents were more likely to have changed sever-
al of their prescribing practices than were respondents in New
Hampshire or Vermont (Table 2).
In Maine only, at posttest, respondents were asked how they used
DA. Eighty-four percent attributed improved attentiveness to pre-
scribing to DA. More than half (59.3%) said they used it as a way
to intervene with patients who were abusing or diverting prescrip-
tions, and 40% used it as tool to screen new patients. Respondents
were also asked to report the number of patients they discovered
on a Diversion Alert report;  52% discovered at least 1 patient,
with an average of 2.5 patients discovered per yes response.
Discussion
It is noteworthy that Maine respondents increased their commu-
nications with others involved in the treatment of their patients but
decreased their communications with law enforcement. This sup-
ports the idea that Diversion Alert is a tool for health care de-
cision-making, not for law enforcement and legal action. Vermont
also showed a significant decrease in communication with law en-
forcement whereas New Hampshire increased on this item. The
absence of the PDMP program, and information provided by it, in
New Hampshire may be associated with a higher degree of inter-
action with law enforcement as the basis for obtaining informa-
tion about patients who may be involved in illegal activity. This
point  should  be  tested,  because  New Hampshire  launched  its
PDMP in October of 2014.
In Maine, significant improvements were realized on communica-
tion and collaboration with patients through contracts, screening to
garner additional information to guide prescribing and treatment
decisions, and more conservative prescribing procedures to limit
illegal  use  and diversion for  patients  who have been arrested.
Moreover, Maine providers significantly decreased discharging
patients who had been arrested, suggesting that they sought to
provide needed health care to all patients while also attending to
alternative prescribing for those who have been involved in illegal
substance activity.
Piper and colleagues’ comprehensive analysis of data in Maine
highlights the utility of Diversion Alert data to describe one as-
pect of the societal ill (15); opioids accounted for more than 50%
of arrests between January 2014 and the first quarter of 2015 (11).
A 2014 survey of Maine pharmacists found that the most agreed-
upon of several pressing issues identified were related to opioid
misuse and diversion (16).  Given this agreed-upon concern of
pharmacists and their expanding role potentially afforded by the
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Affordable Care Act (17), Diversion Alert could be a useful tool,
in addition to the PDMP, to screen patients before filling an opioid
prescription. McCall and colleagues found in a study that linked
Diversion Alert arrest data to patient PDMP records that Diver-
sion  Alert  data  complement  PDMP  data;  76%  of  individuals
charged with prescription drug trafficking in 2014 did not have a
matching record in Maine’s PDMP (18).
Our results are promising, but a limitation of our study is the in-
herent weakness in relying on survey data without psychometric
properties established, a limitation that should be considered. In
addition, the study design was unable to fully account for the his-
torical threat to validity; nationally, attention is being given to the
opioid epidemic, and alternative explanations such as statewide or
national policy change are possible. However, more than 80% of
survey respondents indicated improved attentiveness to prescrib-
ing as a result of Diversion Alert, and almost 60% reported using
it as tool to intervene with patients; therefore, despite limitations,
it appears likely that Diversion Alert could help prevent the abuse
and misuse of opioid medications.
Acknowledgments
The authors acknowledge Elizabeth DePoy, PhD, who completed
the initial analysis of data for an Evaluation Report of Diversion
Alert.
Author Information
Corresponding  Author:  Sarah  Levin  Martin,  PhD,  Husson
University,  School  of  Pharmacy,  1  College  Cir,  Bangor,  ME
04401. Telephone: 207-992-4945. Email: martinsar@husson.edu.
Author Affiliations:  1Husson University,  School  of  Pharmacy,
Bangor Maine. 2Diversion Alert, Houlton, Maine.
References
Paulozzi  L,  Baldwin  G;Centers  for  Disease  Control  and
Prevention. CDC grand rounds: prescription drug overdoses —
a  U.S.  epidemic.  MMWR  Morb  Mortal  Wkly  Rep  2012;
61(1):10–3.
  1.
Jones CM, Paulozzi  LJ,  Mack KA. Sources of prescription
opioid pain relievers by frequency of past-year nonmedical use
United  States,  2008–2011.  JAMA  Intern  Med  2014;
174(5):802–3.
  2.
Hwang CS, Kang EM, Kornegay CJ,  Staffa JA, Jones CM,
McAninch  JK.  Trends  in  the  concomitant  prescribing  of
opioids  and benzodiazepines,  2002–2014.  Am J  Prev  Med
2016;51(2):151–60.
  3.
Centers for Disease Control and Prevention. Opioid painkiller
prescribing.  http://www.cdc.gov/vitalsigns/pdf/2014-07-
vitalsigns.pdf. Accessed June 19, 2015.
  4.
Rudd RA. Increases in drug and opioid overdose deaths —
United States, 2000–2014. Centers for Disease Control and




Haegerich TM, Paulozzi LJ, Manns BJ, Jones CM. What we
know, and don’t know, about the impact of state policy and
systems-level  interventions  on  prescription  drug overdose.
Drug Alcohol Depend 2014;145(145):34–47.
  6.
Jones  CM, Lurie  PG,  Compton WM. Increase  in  naloxone
prescriptions dispensed in US retail pharmacies since 2013.
Am J Public Health 2016;106(4):689–90.
  7.
Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF. Rates
of opioid dispensing and overdose after introduction of abuse-
deterrent  extended-release  oxycodone  and  withdrawal  of
propoxyphene. JAMA Intern Med 2015;175(6):978–87.
  8.
Manasco AT, Griggs C, Leeds R, Langlois BK, Breaud AH,
Mitchell PM, et al. Characteristics of state prescription drug
m o n i t o r i n g  p r o g r a m s :  a  s t a t e - b y - s t a t e  s u r v e y .
Pharmacoepidemiol Drug Saf 2016;25(7):847–51.
  9.
Inciardi JA, Surratt HL, Kurtz SP, Burke JJ. The diversion of
prescription drugs by health care workers in Cincinnati, Ohio.
Subst Use Misuse 2006;41(2):255–64.
10.
Inciardi JA, Surratt HL, Kurtz SP, Cicero TJ. Mechanisms of
prescription drug diversion among drug-involved club- and
street-based populations. Pain Med 2007;8(2):171–83.
11.
Bureau of  Justice  Statistics.  Drugs  and crime facts.  http://
www.bjs.gov/content/dcf/ptrpa.cfm. Accessed July 19, 2016.
12.
The  coalition  impact:  environmental  prevention  strategies.
Alexandria  (VA):  Community  Anti-Drug  Coalitions  of
America; 2008.
13.
Toward a comprehensive, transtheoretical model of change:
stages of change and addictive behaviors. In: DiClemente CC,
Prochaska  JO,  Miller  WR,  Heather  N.  Treating  addictive
behaviors, 2nd edition. New York (NY): Plenum Press; 1998.
p. 3–24.
14.
Piper BJ, Desrosiers CE, Lipovsky JW, Rodney MA, Baker
RP, McCall KL, et al. Use and misuse of opioids in Maine:
results from pharmacists, the Prescription Monitoring and the
Diversion  Alert  Programs.  J  Stud  Alcohol  Drugs  2016;
77(4):556–65.
15.
Martin  SL,  Baker  RP,  Piper  BJ.  Evaluation  of  urban-rural
differences  in  pharmacy  practice  needs  in  Maine  with  the
MaPPNA. Pharm Pract (Granada) 2015;13(4):669.
16.
PREVENTING CHRONIC DISEASE VOLUME 13, E159
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY   NOVEMBER 2016
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
4       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2016/16_0229.htm
McBane  SE,  Dopp  AL,  Abe  A,  Benavides  S,  Chester  EA,
Dixon  DL,  et  al.;American  College  of  Clinical  Pharmacy.
Collaborative drug therapy management and comprehensive
medication  management  — 2015.  Pharmacotherapy  2015;
35(4):e39–50.
17.
McCall K, Nichols SD, Holt C, Ochs L, Cattabriga G, Tu C.
Prescription monitoring program trends among individuals
arrested in Maine for trafficking prescription drugs in 2014.
Pharmacotherapy 2016;36(6):585–9.
18.
PREVENTING CHRONIC DISEASE VOLUME 13, E159
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY   NOVEMBER 2016
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2016/16_0229.htm • Centers for Disease Control and Prevention       5
Tables
Table 1. Provider Awareness and Practice Surveys Completed by State, Northern New England, United States, 2013–2014
State No. of Completed Presurveys
No. of Completed Postsurveys
(% of Prescribers)
Maine 862 202 (81.7)
New Hampshire 580 385 (76.1)
Vermont 369 195 (73.9)
Total 1,811 782
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Table 2. Prescribers’ Reported Behaviors Concerning Narcotics, Northern New England, United States, 2013–2014
Survey Item






I use patient agreements (or contracts) for patients who are prescribed
ongoing therapy with narcotics.
3.06 2.8 2.81 3.31b 2.86 2.84b
I use patient agreements (or contracts) for patients who are prescribed
ongoing therapy with controlled substances other than narcotics.
2.76 1.87 2.08 2.86b,c 2.08 2.16b
I use a screening tool to determine a patients' history of substance abuse or
addiction.
2.4 1.89 2.08 2.39c 2.0 2.09
I order urine toxicology screens on new patients before prescribing a
controlled substance.
2.63 1.76 2.06 2.26c 1.71 1.87
I order random urine toxicology screens on existing patients who are
prescribed a controlled substance.
2.71 2.05 2.34 2.5 2.04 2.19
I speak to patients in my care about my knowledge of their prescription
possession or diversion arrest.
2.82 2.33 2.49 2.71 2.34 2.52b
I share information with colleagues about how best to respond to patients I
discover involved in illegal drug-related activities.
2.74 2.42 2.63 2.75 2.51a 2.57
I share information with colleagues about use of best practices for prescribing
controlled substances.
2.7 2.29 2.45 2.64c 2.33b 2.37
I consult my state’s Prescription Drug Monitoring Programd 2.5 1.43 2.39 3.14b 1.56b 2.79b
If a patient in my care were arrested for a prescription drug-related crime, I
would stop prescribing controlled substances to him/her.
3.38 3.65 3.61 3.51b,e,f 3.64 3.32
Stopped prescribing for patients who have been arrested 3.28 3.3 3.51 3.54b,e 3.68b 3.56b
Do not change meds for patients who have been arrested 2.79 2.65 1.38 1.32b,e 1.28b 1.27b
Refer for addiction counseling NA 3.2e 3.19 3.16
Discharge patients who have been arrested 2.93 2.79 1.98 1.8b,e 2.12b 1.76b
a Values based on Likert scale scores, ranging from 1 =  never to 4 = all the time.
b Indicates significant difference between pre- and post-test within each state.
c Significant difference between Maine and both Vermont and New Hampshire.
d New Hampshire did not have Prescription Drug Monitoring Program at the time of the surveys (established 2014).
e Significant difference between Maine and New Hampshire.
f Significant difference between Maine and Vermont.
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